Phillip Robinson, MD
Family Medicine · Columbus, GANPI 1912908633
Payments from drug & device makers
Across 339 payments — averaging $15.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$824
- Lilly USA, LLC$638
- Astellas Pharma US Inc$356
- Novartis$271
- Amgen$237
- plus $2K from 31 others
What the payments were for
- Food & beverage$5,05695%
- Education$2274%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 101 | $1,202 |
| AbbVie(2 entities) | 44 | $824 |
| Lilly USA, LLC | 53 | $638 |
| Astellas Pharma US Inc | 10 | $356 |
| Novartis | 17 | $271 |
| Amgen(2 entities) | 15 | $237 |
| Myriad Women's Health, Inc. | 2 | $193 |
| Boehringer Ingelheim | 10 | $161 |
| Esperion Therapeutics, Inc. | 9 | $141 |
| Daiichi Sankyo Inc. | 6 | $122 |
| AstraZeneca | 9 | $121 |
| GSK | 8 | $121 |
| Biohaven Pharmaceuticals, Inc. | 6 | $90 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $89 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $84 |
| Pfizer | 5 | $75 |
| Abbott | 3 | $61 |
| Mannkind Corporation | 1 | $59 |
| Amarin Pharma, Inc. | 3 | $57 |
| Merck | 4 | $55 |
| Bayer | 2 | $51 |
| Axsome Therapeutics, Inc. | 3 | $44 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Eisai Inc. | 2 | $29 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Intuitive Surgical | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Seqirus USA Inc | 1 | $18 |
| Exact Sciences | 1 | $17 |
| Tolmar, Inc. | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Bausch Health US, LLC | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Dexcom, Inc. | 1 | $13 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,342 in reported general payments places this provider in the 85th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 92 | $91,321 |
| OzempicSemaglutide | 38 | $35,855 |
| Tresiba Flextouch U-100Insulin Degludec | 27 | $35,176 |
| XareltoRivaroxaban | 17 | $23,795 |
| FarxigaDapagliflozin Propanediol | 24 | $21,982 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $17,454 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $16,655 |
| TradjentaLinagliptin | 17 | $12,866 |
| RybelsusSemaglutide | 11 | $12,390 |
| JanuviaSitagliptin Phosphate | 12 | $11,499 |
| Testosterone | 36 | $9,752 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $7,194 |
| JardianceEmpagliflozin | 12 | $6,959 |
| Novolog FlexpenInsulin Aspart | 16 | $6,778 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $5,837 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $75 | $91,32192 claims |
| Novo NordiskOzempic, Rybelsus | $1,202 | $48,24649 claims |
| AstraZenecaFarxiga, Symbicort | $121 | $29,17747 claims |
| Boehringer IngelheimTradjenta, Jardiance | $161 | $19,82529 claims |
| GSKTrelegy Ellipta | $121 | $16,65516 claims |
| MerckJanuvia | $55 | $11,49912 claims |
| AbbVieSynthroid | $824 | $2,26956 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Columbus
- Joseph SurberColumbus$16.6M
- Jeffrey KingsleyColumbus$8.1M
- Bantwal BaligaColumbus$117K
- Megbewe OkorobaColumbus$61K
- Kimberly Brown-GullattColumbus$35K
- Angela RitterGainesville$15.8M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.